Literature DB >> 18319567

Phenoxazine derivatives inactivate human cytomegalovirus, herpes simplex virus-1, and herpes simplex virus-2 in vitro.

Kyoko Hayashi1, Toshimitsu Hayashi, Akio Tomoda.   

Abstract

We examined whether phenoxazine derivatives, 2-amino-4,4alpha-dihydro-4alpha-7-dimethyl-3H-phenoxazine-3-one (Phx-1), 3-amino-1,4alpha-dihydro-4alpha-8-dimethyl-2H-phenoxazine-2-one (Phx-2), and 2-amino-phenoxazine-3-one (Phx-3) may have antiviral activity against herpes family viruses: human cytomegalovirus (HCMV), herpes simplex virus type 1 (HSV-1), and herpes simplex virus type 2 (HSV-2). The antiviral activity was evaluated by the selectivity index (SI), which is the ratio of 50% cytotoxic concentration (CC(50)) and 50% antiviral concentration (IC(50)). Among these phenoxazines, Phx-2 exerted strong antiviral activity to HCMV with the SI of 200, while Phx-1 and Phx-3 exerted no marked anti-HCMV activity. Phx-2 also showed moderate inhibition of HSV-1 and HSV-2, with the SI of 6.7 and 17, respectively. In the time-of-addition experiments, inhibitory effect of Phx-2 against HCMV was active even when applied to cells at 100 h after HCMV infection, while ganciclovir (GCV) showed potent inhibition when applied to cells before 42-h post-infection, but its inhibitory effects disappeared thereafter. Attachment and penetration of HCMV was not affected by the presence of Phx-2. When HCMV was pretreated with Phx-2, concentration-dependent virucidal action was observed, suggesting that Phx-2 inactivates HCMV directly. From these data, it was found that Phx-2 might have a different anti-HCMV target from GCV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18319567     DOI: 10.1254/jphs.fp0071679

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  7 in total

1.  Production of 2-aminophenoxazin-3-one by Staphylococcus aureus causes false-positive results in β-galactosidase assays.

Authors:  Herman Tse; Elaine Chan; Ching-Wan Lam; Ka-Fai Leung; Pat Chow; Kim-Chung Lee; Kong-Hung Sze; Stanley K K Cheung; Man-Kit Tse; Pak-Leung Ho; Sze-Pui Leung; Susanna K P Lau; Patrick C Y Woo; Kwok-Yung Yuen
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

2.  Sulfated derivatives of Escherichia coli K5 capsular polysaccharide are potent inhibitors of human cytomegalovirus.

Authors:  Beatrice Mercorelli; Pasqua Oreste; Elisa Sinigalia; Giulia Muratore; David Lembo; Giorgio Palù; Arianna Loregian
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

3.  In vitro and in vivo antiherpetic effects of (1R,2R)-1-(5'-methylful-3'-yl)propane-1,2,3-triol.

Authors:  Kohei Sasaki; Kyoko Hayashi; Yuji Matsuya; Kenji Sugimoto; Jung-Bum Lee; Fumiya Kurosaki; Toshimitsu Hayashi
Journal:  J Nat Med       Date:  2016-01-13       Impact factor: 2.343

Review 4.  Advances and Perspectives in the Management of Varicella-Zoster Virus Infections.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Molecules       Date:  2021-02-20       Impact factor: 4.411

5.  In Silico Evaluation of Sesquiterpenes and Benzoxazinoids Phytotoxins against Mpro, RNA Replicase and Spike Protein of SARS-CoV-2 by Molecular Dynamics. Inspired by Nature.

Authors:  Francisco J R Mejías; Alexandra G Durán; Nuria Chinchilla; Rosa M Varela; José A Álvarez; José M G Molinillo; Francisco García-Cozar; Francisco A Macías
Journal:  Toxins (Basel)       Date:  2022-08-29       Impact factor: 5.075

Review 6.  Pharmacological Activities of Aminophenoxazinones.

Authors:  Jesús G Zorrilla; Carlos Rial; Daniel Cabrera; José M G Molinillo; Rosa M Varela; Francisco A Macías
Journal:  Molecules       Date:  2021-06-07       Impact factor: 4.411

Review 7.  Prevention of carcinogenesis and development of gastric and colon cancers by 2-aminophenoxazine-3-one (Phx-3): direct and indirect anti-cancer activity of Phx-3.

Authors:  Akio Tomoda; Keisuke Miyazawa; Takafumi Tabuchi
Journal:  Int J Mol Sci       Date:  2013-08-28       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.